Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No allergic history of Anlotinib~* 18-75 years~* No history of severe arrhythmia or heart failure~* No history of severe ventilation dysfunction or severe pulmonary infection~* No acute or chronic renal failure, creatinine clearance \> 40 mL/min~* Liver function is normal: child-pugh grade A or grade B (≤7 points), total bilirubin ≤ 3.0 mg/dL, albumin ≥ 28 g/L, AST, ALT, ALP≤ 5 times of the upper limit of normal value~* Blood test: the absolute neutrophil count ≥ 1.5×10\^9 /L, Hb ≥ 8.5 g/L, PLT ≥ 75×10\^9 /L (without blood transfusions and drug therapy 14 days before the screening)~* Blood coagulation function: INR≤2.3~* ECOG: 0-2~* Pathology: hepatocellular carcinoma~* Satisfy any of the following:~A. portal vein, hepatic vein or bile duct carcinoma thrombus B. microvascular invasion (MVI) grade II (\> 5 MVI, or MVI occurs in the area more than 1 cm from the tumor) C. tumor number ≥ 3 D. preoperative rupture of tumor or tumor invasion adjacent organs~* Patients participate in the study voluntarily and sign informed consent~Exclusion Criteria:~* Pregnant or lactating women~* Patients who have had or are currently complicated with other malignant tumors~* Recurrent hepatocellular carcinoma~* Patients who participated in other clinical trials within 1 month~* Patients with mental illness~* Patients treated with targeted drugs, immunotherapy (such as PD1 antibody), FOLFOX systemic chemotherapy or huaier granules after surgery~* Urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Anlotinib (Type: EXPERIMENTAL): Administration Anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).